Ligand Pharmaceuticals Incorporated (LGND) Financial Statements (2023 and Earlier)
Company Profile
| Business Address |
3911 SORRENTO VALLEY BLVD SAN DIEGO, CA 92121 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance Sheet (Statement of Financial Position) ($ in millions)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 341 | 411 | 1,012 | 718 | 202 | 141 | 200 | ||
| Cash and cash equivalents | 20 | 48 | 72 | 117 | 21 | 19 | 97 | ||
| Short-term investments | 322 | 364 | 940 | 601 | 181 | 122 | 103 | ||
| Restricted cash and investments | 1 | ||||||||
| Receivables | 92 | 59 | 42 | 56 | 26 | 15 | 6 | ||
| Inventory, net of allowances, customer advances and progress billings | 27 | 26 | 7 | 7 | 4 | 2 | 2 | ||
| Inventory | 27 | 26 | 7 | 7 | 4 | 2 | 2 | ||
| Derivative instruments and hedges, assets | 23 | ||||||||
| Other current assets | 5 | 4 | 5 | 20 | 2 | 2 | 2 | ||
| Other undisclosed current assets | 58 | 46 | 4 | 3 | 6 | ||||
| Total current assets: | 465 | 501 | 1,124 | 871 | 237 | 163 | 216 | ||
| Noncurrent Assets | |||||||||
| Finance lease, right-of-use asset | 16 | 16 | ✕ | ✕ | ✕ | ✕ | |||
| Operating lease, right-of-use asset | 17 | 7 | 10 | ✕ | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 21 | 14 | 7 | 5 | 4 | 2 | 0 | ||
| Long-term investments and receivables | 6 | 8 | 30 | ||||||
| Long-term investments | 6 | 8 | 30 | ||||||
| Intangible assets, net (including goodwill) | 732 | 785 | 306 | 306 | 315 | 277 | 61 | ||
| Goodwill | 181 | 190 | 95 | 87 | 86 | 72 | 12 | ||
| Intangible assets, net (excluding goodwill) | 551 | 595 | 210 | 220 | 229 | 205 | 48 | ||
| Regulated entity, other noncurrent assets | 3 | ||||||||
| Deferred income tax assets | 34 | 24 | 26 | ✕ | ✕ | ✕ | ✕ | ||
| Other noncurrent assets | 3 | 4 | 2 | 0 | 5 | 2 | 0 | ||
| Deferred tax assets, net | ✕ | ✕ | ✕ | 124 | 217 | ||||
| Other undisclosed noncurrent assets | 10 | 11 | 20 | 78 | 104 | 26 | 9 | ||
| Total noncurrent assets: | 833 | 862 | 371 | 390 | 434 | 439 | 318 | ||
| TOTAL ASSETS: | 1,298 | 1,362 | 1,495 | 1,261 | 671 | 602 | 534 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 26 | 22 | 12 | 23 | 10 | 9 | 9 | ||
| Accounts payable | 8 | 4 | 2 | 4 | 2 | 3 | 4 | ||
| Accrued liabilities | 18 | 19 | 10 | 19 | 7 | 6 | 5 | ||
| Deferred revenue | 11 | 29 | 2 | ✕ | ✕ | ✕ | ✕ | ||
| Debt | 0 | 7 | 1 | 26 | 225 | 213 | |||
| Derivative instruments and hedges, liabilities | 23 | ||||||||
| Contract with customer, liability | ✕ | ✕ | ✕ | 3 | ✕ | ✕ | ✕ | ||
| Other liabilities | 0 | ||||||||
| Other undisclosed current liabilities | 5 | 42 | 1 | 6 | 5 | 5 | 11 | ||
| Total current liabilities: | 42 | 100 | 17 | 82 | 239 | 227 | 21 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 336 | 448 | 649 | 610 | 205 | ||||
| Long-term debt, excluding current maturities | 321 | 442 | 639 | 610 | 205 | ||||
| Finance lease, liability | 0 | 0 | ✕ | ✕ | ✕ | ✕ | |||
| Operating lease, liability | 15 | 6 | 10 | ✕ | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt | 90 | 95 | 55 | 1 | 4 | 1 | 0 | ||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | 4 | ||||
| Deferred income tax liabilities | 59 | 65 | 33 | ✕ | ✕ | ✕ | ✕ | ||
| Other liabilities | 31 | 31 | 22 | 1 | 1 | 1 | 0 | ||
| Other undisclosed noncurrent liabilities | 8 | 9 | 6 | 7 | 9 | 3 | 3 | ||
| Total noncurrent liabilities: | 435 | 553 | 711 | 618 | 14 | 4 | 209 | ||
| Total liabilities: | 476 | 653 | 728 | 700 | 252 | 231 | 230 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 821 | 710 | 767 | 561 | 400 | 341 | 304 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 373 | 318 | 367 | 791 | 798 | 770 | 701 | ||
| Accumulated other comprehensive income (loss) | (1) | (1) | (0) | (1) | 2 | 3 | 5 | ||
| Retained earnings (accumulated deficit) | 449 | 392 | 400 | (229) | (401) | (431) | (402) | ||
| Total stockholders' equity: | 821 | 710 | 767 | 561 | 400 | 341 | 304 | ||
| Other undisclosed liabilities and equity | 19 | 30 | |||||||
| TOTAL LIABILITIES AND EQUITY: | 1,298 | 1,362 | 1,495 | 1,261 | 671 | 602 | 534 | ||
Income Statement (P&L) ($ in millions)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 277 | 186 | 120 | 251 | 141 | 109 | 72 | |
| Revenue, net | ✕ | ✕ | ✕ | ✕ | 111 | 82 | 66 | |
| Cost of revenue (Cost of Goods and Services Sold) | (47) | (23) | (17) | (6) | (12) | (6) | (1) | |
| Gross profit: | 230 | 163 | 103 | 245 | 129 | 103 | 71 | |
| Operating expenses | (198) | (178) | (126) | (88) | (73) | (65) | (45) | |
| Other undisclosed operating income | 47 | 41 | 830 | 6 | 12 | 6 | 1 | |
| Operating income: | 79 | 26 | 807 | 164 | 68 | 44 | 27 | |
| Nonoperating income (expense) | (32) | (36) | (10) | 10 | (11) | (36) | 8 | |
| Investment income, nonoperating | (3) | (9) | 31 | 14 | 28 | |||
| Other nonoperating income (expense) | (9) | (0) | (6) | (6) | 5 | 3 | 2 | |
| Interest and debt expense | (7) | (27) | (36) | (48) | ||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 27 | 36 | 48 | |||||
| Income (loss) from continuing operations before equity method investments, income taxes: | 40 | (11) | 797 | 173 | 57 | 8 | 35 | |
| Income from equity method investments | 3 | |||||||
| Other undisclosed income from continuing operations before income taxes | 7 | |||||||
| Income (loss) from continuing operations before income taxes: | 47 | (11) | 800 | 173 | 57 | 8 | 35 | |
| Income tax expense (benefit) | 10 | 8 | (167) | (30) | (45) | (10) | 220 | |
| Income (loss) from continuing operations: | 57 | (3) | 632 | 143 | 13 | (2) | 255 | |
| Income from discontinued operations | 1 | |||||||
| Income (loss) before gain (loss) on sale of properties: | 57 | (3) | 632 | 143 | 13 | (2) | 255 | |
| Other undisclosed net loss | (3) | |||||||
| Net income (loss): | 57 | (3) | 629 | 143 | 13 | (2) | 255 | |
| Net income attributable to noncontrolling interest | 2 | |||||||
| Net income (loss) available to common stockholders, diluted: | 57 | (3) | 629 | 143 | 13 | (2) | 257 | |
Comprehensive Income ($ in millions)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 57 | (3) | 629 | 143 | 13 | (2) | 255 | |
| Other comprehensive income (loss) | 0 | (0) | (2) | |||||
| Comprehensive income (loss): | 57 | (3) | 629 | 143 | 12 | (4) | 255 | |
| Comprehensive income, net of tax, attributable to noncontrolling interest | 2 | |||||||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (0) | (1) | 1 | (1) | (0) | |||
| Comprehensive income (loss), net of tax, attributable to parent: | 57 | (4) | 630 | 142 | 12 | (4) | 257 | |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.